Website: N/A
Stock Symbol: NASDAQ: FACT
Market Value: N/A (in millions)
We are a biotechnology company dedicated to advancing our pipeline of
several clinical-stage products and expanding and deriving value from our
proprietary next-generation protein engineering platform technologies to improve
the clinical performance of protein therapeutics.
At the beginning of 2008, PDL operated three businesses: (1) the
biotechnology business (Biotechnology Business), (2) the antibody humanization
patents licensing and royalty business (Royalty Business) and (3) the
development, sale and marketing of non-antibody commercial products (Commercial
and Cardiovascular Business). During 2008, PDL decided to spin off its
Biotechnology Business (the Spin-off). In July 2008, in preparation for the
Spin-off, PDL organized Facet Biotech as a Delaware corporation and a wholly
owned subsidiary of PDL.